Related Tags >> vertex Hepatitis C Merck boceprevir

telaprevir News

Most Popular telaprevir Story

Vertex outlines its survival plan for next-gen hep C combo

January 24, 2012 — 8:52am ET | By John Carroll

At the beginning of 2011, Vertex ($VRTX) was basking in the limelight of blockbuster success. Its hepatitis C drug was headed for approval, offering a game-changing approach to the disease, and was Read more...

telaprevir Press Releases

The Hepatitis C Virus Drug Market Will Experience Dramatic Near-Term Growth, Increasing from $1.7 Billion in 2010 to $16 B
Hepatitis C Specialists Report Similar Trial Rates for Merck/Roche’s Victrelis and Vertex’s Incivek, but Incivek is Likely
Massive Opportunity Exists in Hepatitis C Market for Recently Approved Protease Inhibitors Victrelis and Incivek According
FDA Advisory Committee Unanimously Recommends Approval of Telaprevir for People with Hepatitis C
For Treatment of HCV, Surveyed European Gastroenterologists Will Prescribe Telaprevir and Boceprevir to Nonresponder and T

Latest Headlines

Vertex outlines its survival plan for next-gen hep C combo
January 24, 2012
Pfizer, J&J grab CHMP backing for key new drugs
July 22, 2011
Vertex victory triggers big HQ move as Biogen ponders the future
May 24, 2011
FDA approves mega-blockbuster Vertex hep C drug Incivek
May 23, 2011
UPDATED: J&J is on a roll as drug deals deliver blockbuster approvals
May 23, 2011
Hold your breath for Vertex's big telaprevir moment
May 20, 2011
FDA panel unanimously backs Vertex's Hep C drug telaprevir
April 29, 2011
Vertex offers a blockbuster case for telaprevir
April 28, 2011
Merck wins unanimous FDA panel support for blockbuster boceprevir
April 28, 2011
FDA team applauds telaprevir's efficacy, raises safety concerns
April 26, 2011
Confident of success, Vertex plans gangbuster rollout of telaprevir
April 25, 2011
Two new hep C drugs garner rave reviews ahead of approval
March 31, 2011
Vertex boosted by new round of promising telaprevir data
March 3, 2011
Vertex wins an expedited review of telaprevir app
January 20, 2011
Merck scoots past Vertex in blockbuster race for hep C drug approval
January 6, 2011
Vertex trims a telaprevir study from its slate of hep C work
December 22, 2010
Vertex scrambles for quick OK of blockbuster telaprevir app
November 23, 2010
Vertex's telaprevir cuts hep C treatment time in half
August 10, 2010
Merck's boceprevir scores high in PhIII hep C trial
August 4, 2010
With losses rising, Vertex rolls out its telaprevir app
July 29, 2010

Paid Research Reports

More Research Reports >>

Free Newsletter

Most Popular Stories

Webinars

Hottest Products

Featured Jobs

Events